Amplified in tumors

Articles

• EZH2
  23 January 2006

  Enhancer of zeste homolog 2 (EZH2) WKP
  Definition: Ezh2 is a polycomb group protein. EZH2 is known to function in histone methylation, thereby regulating gene expression.
  Ezh2-containing complex has been given an additional role in cellular regulation. Cytosolic Ezh2 methyltransferase complexes were shown to associate with Vav1 and control receptor-induced actin polymerization and proliferation in a methylation-dependent manner.
  Overall, lysine methylation is a posttranslational (...)

• MYCN
  18 April 2005

  NMYC, N-MYC

• REL
  9 January 2007

  c-rel

• IKBKE
  29 August 2008

  Pathology
  amplified by amp(1)(q32.1) in mammary carcinomas (breast cancer)

• YEATS4
  30 September 2008

  Definition: YEATS4 is a transcription factor.
  Shown to inhibit p53 transactivation activity and decrease the p53 proapoptotic response, the inhibition of YEATS4 results in p53 stabilization and activation.
  Pathology
  YEATS4 is a transcription factor amplified in human gliomas.
  YEATS4 (GAS41) as a novel oncogene important in the pathogenesis of WDLPS/DDLPS (well-differentiared liposarcoma/dedifferentiated liposarcoma).
  The functional impairment of the p53 pathway plays a crucial role (...)

• DYRK2
  30 September 2008

  Human fetal brain DYRK2 (GenBank Y13493) cDNAs encode 2 isoforms: a deduced 528-amino acid protein and a protein containing 73 additional amino acids at the N terminus.
  The DYRK2 proteins contain a canonical kinase domain located between a large N-terminal region and a short C-terminal extension, and features specific to DYRK-related kinases.
  DYRK2 shares 46% identity with DYRK1 in the catalytic domain, but lacks the striking sequence motifs identified in DYRK1.
  The DYRK2 and DYRK3 (...)

• ERBB2
  11 February 2006

  ERBB2 ; CD340; HER-2; HER-2/neu; HER2; MLN 19; NEU; NGL; TKR1; c-erbb2
  The oncogene originally called HER/NEU was derived from rat neuro/glioblastoma cell lines. It encodes a tumor antigen, p185, which is serologically related to EGFR, the epidermal growth factor receptor (MIM.131550).
  ERBB2 encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases (ERBBs).
  ERBB2 has no ligand binding domain of its own and therefore cannot bind growth factors. (...)

• NACC1
  26 May 2011

  nucleus accumbens associated 1, BEN and BTB (POZ) domain containing

• WNT5B
  18 January 2005

  Pathology
  association with type 2 diabetes (#15386214#)
  12p13 amplification in tumors pediatric malignant astrocytoma (#20068183#)
  References
  Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD. Cancer Res. 2010 Jan 15;70(2):512-9. PMID: (...)

• GPC5
  21 September 2004

  glypican-5, GLYPICAN 5, GPC5

0 | 10 | 20